MRL828
MRL828 is a heterobifunctional molecule that targets aggregated tau protein. As an autophagy-targeting chimera (ATTEC), MRL828 selectively labels aggregated tau protein for clearance via the autophagy (autophagy)-lysosome pathway. The activity of MRL828 depends on autophagosomes rather than lysosomes, and it induces autophagosome-dependent secretion. MRL828 acts as an intracellular aggregate inhibitor and a secretory autophagy inducer, reducing intracellular levels of aggregated tau protein through autophagosome-dependent secretory autophagy instead of lysosomal degradation. MRL828 can be used in the research of neurodegenerative diseases such as Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 3115333-82-6
- Formula: C46H51FN14O5S
- Molecular Weight:931.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Tau aggregates 50 nM (DC50) |
In Vitro
MRL828 (0.1-10 μM; 48 h) potently reduces aggregated tau in tau aggregation-induced CHO T-REx P301L cells with a DC50 of 20 nM, while exerting minimal effects on cell viability. Its pharmacodynamic activity depends on the combined action of the tau-binding domain and the autophagy-targeting domain[1].
The reduction of aggregated tau induced by MRL828 (1 μM; 24-48 h) in tau aggregation-induced CHO T-REx P301L cells depends on p62 and VPS34, components of the autophagy pathway[1].
MRL828 (1 μM; 48 h) selectively reduces aggregated and phosphorylated tau species in tau aggregation-induced CHO T-REx MAPTP301L cells, with the greatest reduction observed in detergent-insoluble tau aggregates[1].
MRL828 (1 μM; 24-48 h) reduces aggregated tau in tau aggregation-induced CHO T-REx tauP301L cells via an autophagy-dependent, lysosome-independent mechanism that involves increased secretion levels of oligomerized and phosphorylated tau isoforms[1].
MRL828 (1 μM, 24-48 h) still reduces tau aggregates in the presence of Bafilomycin A1 (HY-100558, 25 nM) or Hydroxychloroquine (HY-W031727, 15 μM), and does not increase the colocalization of MC1-positive tau puncta with the lysosomal marker LAMP2 at 24 h, indicating that its mechanism of action is independent of lysosomes.[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:tau aggregation-induced CHO T-REx P301L cells
-
Concentration:1 μM (MRL828); 100 nM (Bafilomycin A1 for LC3-II analysis); 25 nM (Bafilomycin A1 for DQ-BSA imaging)
-
Incubation Time:MRL828 44 h followed by Bafilomycin A1 cotreatment for 4 h for LC3-II analysis; MRL828 or Bafilomycin A1 48 h, with DQ-BSA added 6 h before the end of treatment
-
Result:Did not alter LC3-II accumulation, and showed the same Bafilomycin A1-induced LC3-II accumulation as vehicle-treated cells.
Did not impair DQ-BSA-based lysosomal proteolysis, indicating no change in lysosomal degradation capacity.
Chemical Information
-
CAS No. 3115333-82-6
-
Molecular Weight 931.05
-
Formula C46H51FN14O5S
-
SMILES
O=C(NCCCOCCCCOCCCNC1=NC=C(C#CC2=CC=C(C3=CN4C=C(CO)C=CC4=N3)N=C2)C=N1)[C@@H](NC(C)=O)CSC5=NC6=C(N)N=C(N)N=C6N5CC7=CC=C(F)C=C7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)